- Home
- NNBR vs LPTX Comparison
NNBR vs LPTX Comparison
Compare NNBR & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- LPTX
- Stock Information
- Founded
- NNBR 1980
- LPTX 2011
- Country
- NNBR United States
- LPTX United States
- Employees
- NNBR N/A
- LPTX N/A
- Industry
- NNBR Industrial Machinery/Components
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNBR Industrials
- LPTX Health Care
- Exchange
- NNBR Nasdaq
- LPTX Nasdaq
- Market Cap
- NNBR 149.8M
- LPTX 119.6M
- IPO Year
- NNBR 1994
- LPTX N/A
- Fundamental
- Price
- NNBR $2.49
- LPTX $0.40
- Analyst Decision
- NNBR
- LPTX Buy
- Analyst Count
- NNBR 0
- LPTX 3
- Target Price
- NNBR N/A
- LPTX $8.50
- AVG Volume (30 Days)
- NNBR 195.3K
- LPTX 369.2K
- Earning Date
- NNBR 03-05-2025
- LPTX 03-17-2025
- Dividend Yield
- NNBR N/A
- LPTX N/A
- EPS Growth
- NNBR N/A
- LPTX N/A
- EPS
- NNBR N/A
- LPTX N/A
- Revenue
- NNBR $464,290,000.00
- LPTX N/A
- Revenue This Year
- NNBR N/A
- LPTX N/A
- Revenue Next Year
- NNBR $0.69
- LPTX N/A
- P/E Ratio
- NNBR N/A
- LPTX N/A
- Revenue Growth
- NNBR N/A
- LPTX N/A
- 52 Week Low
- NNBR $2.38
- LPTX $0.39
- 52 Week High
- NNBR $5.20
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- NNBR 35.59
- LPTX 19.10
- Support Level
- NNBR $2.53
- LPTX $0.40
- Resistance Level
- NNBR $2.74
- LPTX $0.46
- Average True Range (ATR)
- NNBR 0.18
- LPTX 0.03
- MACD
- NNBR -0.04
- LPTX 0.07
- Stochastic Oscillator
- NNBR 2.86
- LPTX 13.64
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets. It also operates in China, Mexico, Brazil, Germany, and other countries.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .